EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...

X4 Pharmaceuticals, Inc.’s XFOR share price has surged by 52.59%, which has investors questioning if this is right time to ...

Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome ...

Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for ...

WHIM syndrome is named for its four classic manifestations: warts, hypogammaglobulinemia, infections, and myelokathexis, although only a minority of patients experience all four manifestations in ...

KUDO, the world's leading provider of language accessibility technology, has announced the release of its revamped mobile app for real-time, on-demand conversational speech translation. Available on ...

The investments needed to tackle the province's primary care crisis, shore up the nursing workforce and address issues of housing affordability and accessibility were outlined today by the president ...

for the treatment of patients with agammaglobulinemia or hypogammaglobulinemia. These conditions, characterized by low or absent antibody levels, result in an increased risk of serious infections.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

The adaptive immune system is an antigen-specific structure that discriminates non-self molecules through the recognition of peptide antigens using receptor interactions between T-cells and ...

In contrast to acquired rubella infection, congenital infection results in persistent progressive infection. Contact isolation is required for neonates suspected to have congenital rubella.

After hours: January 28 at 5:55:39 p.m. EST ...